Inactive Instrument

tella, Inc.

Equities

2191

JP3545900007

Biotechnology & Medical Research

Cenegenics Japan Co., Ltd. agreed to acquire 51% stake in Prometheus. Biotech Corporation. from tella, Inc. for ¥153 million.

December 24, 2020

Cenegenics Japan Co., Ltd. agreed to acquire 51% stake in Prometheus. Biotech Corporation. from tella, Inc. (JASDAQ:2191) for ¥153 million on December 25, 2020. Cenegenics Japan will acquire 1,530 common shares of Prometheus. Biotech Corporation. The transaction was resolved by the Board of tella, Inc. on December 25, 2020. The transaction is expected to close on December 28, 2020.

Latest news about tella, Inc.

Tella, Inc.(JASDAQ:2191) dropped from S&P Global BMI Index	21-09-20	CI
Beroni Group Signs Mou with tella, Inc. to Collaborate in Immunotherapy for Cancer Treatment	21-05-28	CI
Argentina Tries to Tax and Spend Its Way Out of an Economic Crisis	21-03-09	DJ
Cenegenics Japan Co., Ltd. completed the acquisition of 51% stake in Prometheus. Biotech Corporation. from tella, Inc..	20-12-27	CI
Cenegenics Japan Co., Ltd. agreed to acquire 51% stake in Prometheus. Biotech Corporation. from tella, Inc. for ¥153 million.	20-12-24	CI
Tella, Inc. announced that it has received ¥1.0010013 billion in funding from Cenegenics Japan Co., Ltd.	20-12-15	CI
Tella, Inc. announced that it expects to receive ¥1.0010013 billion in funding from Cenegenics Japan Co., Ltd.	20-10-27	CI
Tella, Inc.(JASDAQ:2191) added to S&P Global BMI Index	20-09-21	CI
Argentina defuses default crisis with 'massive' debt deal	20-09-01	RE
Tella, Inc. acquired 51% stake in Prometheus Biotech Corporation from Cenegenics Japan Co., Ltd. for approximately ¥150 million.	20-08-25	CI
Shogo Kozuka cancelled the acquisition of TITAN Inc. from tella, Inc. from tella, Inc..	20-08-14	CI
Now for the hard part: Argentina must fix economy after debt deal	20-08-05	RE
Shogo Kozuka agreed to acquire TITAN Inc. from tella, Inc. from tella, Inc..	19-08-14	CI
Tella, Inc. announced that it has received ¥3.66 million in funding from Evolution Capital Management, LLC	19-06-30	CI
Tella, Inc. announced that it expects to receive ¥3.54 million in funding from Evolution Capital Management, LLC	19-06-06	CI
Tella, Inc. announced that it has received ¥209.3312 million in funding from E-4B Investments Co., Ltd	18-06-28	CI
Tella, Inc. announced that it expects to receive ¥209.3312 million in funding from E-4B Investments Co., Ltd	18-06-12	CI
Tella, Inc. Announces Consolidated and Non-Consolidated Earnings Results for the Nine Months Ended December 31, 2017; Provides Consolidated Earnings Guidance for the Half Year Ending June 30, 2018 and Full Year Ending December 31, 2018	18-02-12	CI
Daiki Holdings Co., Ltd. cancelled the acquisition of Tella Small Amount Short Term Insurance Co., Ltd. from Tella, Inc..	17-08-25	CI
Tella, Inc. announced that it has received ¥982 million in funding from Rheos Capital Works Inc	17-07-17	CI
Tella, Inc. announced that it expects to receive ¥982 million in funding from Rheos Capital Works Inc	17-06-29	CI
Bellwood Enterprise Co., Ltd. acquired 11.28% stake in Tella, Inc. from Yuchiro Yazaki.	17-02-14	CI
Tella, Inc. announced that it has received ¥2.49 million in funding from Morgan Stanley MUFG Securities Co., Ltd.	16-12-28	CI
Tella, Inc. announced that it expects to receive ¥2.49 million in funding from Morgan Stanley MUFG Securities Co., Ltd.	16-12-12	CI
Tella, Inc.(JASDAQ:2191) dropped from S&P Global BMI Index	16-09-19	CI

Chart tella, Inc.

Duration

Period

More charts

Company Profile

tella, Inc. is a Japan-based company mainly engaged in the provision of techniques and operational knowhow associated with cell medicines, as well as the research and development of regenerative medicine and cell medicine. The Company operates through three business segments. The Cell Medicine segment is engaged in the provision of cancer treatment technology and operational method centered on dendritic cell vaccine therapy. This segment is also engaged in the provision of Services for contract medical institutions, such as cell culture system maintenance support services, management system maintenance support services and disease support services. The Medical Support segment is mainly engaged in the provision of drug development services (CROs) and genetic testing services. The Pharmaceutical segment is engaged in the development of the dendritic cell vaccine for regulatory approval as a product for cancer regenerative medicine.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+26.28%	42.68B
IQVIA HOLDINGS INC.	-3.99%	42.4B
LONZA GROUP AG	+45.32%	40.04B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+6.36%	24.94B
ALNYLAM PHARMACEUTICALS, INC.	-21.47%	18.96B
MEDPACE HOLDINGS, INC.	+27.58%	12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.75%	11.95B
BIO-TECHNE CORPORATION	-2.02%	11.55B

Other Biotechnology & Medical Research